Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | CTSL | P07711 | 3/20 | 0.74 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.69 |
| ▸ | CDK2 | P24941 | 3/20 | 0.69 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | CDK1 | P06493 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197484 | 0.91 | TDP1 (0.67) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6945139 | 0.90 | TDP1 (0.65) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6945307 | 0.90 | TDP1 (0.64) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL29356768 | 0.89 | TDP1 (1.00) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6817715 | 0.88 | CTSL (0.76) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL4487915 | 0.87 | TDP1 (0.61) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL5763160 | 0.87 | YTHDC1 (0.64) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL29659669 | 0.87 | YTHDC1 (0.64) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL15940797 | 0.86 | CTSL (0.64) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6820578 | 0.86 | CTSL (0.64) | TDP1CTSLCCNE1CDK2CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | TDP1 210/4885CTSL 2469/4885CCNE1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.